Dashboard
Manage Tickers

GMABGENMAB A/S

Nasdaq genmab.com


$ 27.90 $ -0.53 (-1.86 %)    

Tuesday, 28-May-2024 15:15:04 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -0.57 (-0.12 %)
DIA $ 398.57 $ -2.01 (-0.52 %)
SPY $ 530.36 $ -1.80 (-0.34 %)
TLT $ 91.26 $ -1.19 (-1.31 %)
GLD $ 225.37 $ 0.20 (0.09 %)
$ 28
$ 28.43
$ 27.90 x 100
$ 27.99 x 102
$ 27.90 - $ 28.46
$ 26.32 - $ 42.72
594,512
na
126M
$ 0.78
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

intuit-workday-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Intuit, Workday And Other Big Stocks Movin...
05/24/2024 09:45:52

what-9-analyst-ratings-have-to-say-about-genmab
What 9 Analyst Ratings Have To Say About G...
05/20/2024 15:00:19

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
05/20/2024 10:26:42

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-announces-presentation-of-multiple-abstracts-on-epcoritamab-at-2024-european-hematology-association-congress-on-june-13-16
Genmab Announces Presentation Of Multiple ...
05/14/2024 14:10:14

genmab-announces-presentation-of-multiple-abstracts-on-epcoritamab-at-2024-european-hematology-association-congress-on-june-13-16-2024
Genmab Announces Presentation Of Multiple ...
05/14/2024 14:09:41

Core News & Articles
Watching Genmab; Shares Trading Higher Aft...
05/13/2024 16:00:50

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
05/03/2024 19:59:17

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-q1-2024-revenue-60425m
Genmab Q1 2024 Revenue $604.25M
05/02/2024 15:05:48

decoding-9-analyst-evaluations-for-genmab
Decoding 9 Analyst Evaluations For Genmab
04/30/2024 12:00:57

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
04/30/2024 10:22:57

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

Core News & Articles
FDA OKs Seagen's Tivdak (tisotumab vedotin...
04/29/2024 19:53:09

- Bloomberg

genmab-reports-darzalex-q1-net-sales-of-2692b
Genmab Reports DARZALEX Q1 Net Sales Of $2...
04/16/2024 10:42:24

profoundbio-discovers-the-joys-of-having-a-wealthy-owner
ProfoundBio Discovers The Joys Of Having A...
04/08/2024 15:43:57

Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The d...

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
04/04/2024 15:26:23

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-to-acquire-profoundbio-for-18b-cash-enhancing-and-expanding-its-oncology-portfolio
Genmab To Acquire ProfoundBio For $1.8B Ca...
04/03/2024 05:42:07

Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in...

hc-wainwright--co-maintains-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Maintains Buy on Genma...
03/27/2024 10:29:18

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

morgan-stanley-maintains-underweight-on-genmab-maintains-32-price-target
Morgan Stanley Maintains Underweight on Ge...
03/26/2024 15:03:49

Morgan Stanley analyst Matthew Harrison maintains Genmab (NASDAQ:GMAB) with a Underweight and maintains $32 price target.

analyst-ratings-for-genmab
Analyst Ratings For Genmab
03/26/2024 14:00:35

truist-securities-maintains-buy-on-genmab-maintains-50-price-target
Truist Securities Maintains Buy on Genmab,...
03/26/2024 13:29:43

Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-announces-initiation-dkk35b-share-buy-back-program
Genmab Announces Initiation DKK3.5B Share ...
03/15/2024 12:19:25

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION